-+ 0.00%
-+ 0.00%
-+ 0.00%

Dermata Therapeutics Q3 2026 net loss widens 67% to USD 2.82 million

PUBT·11/10/2026 22:09:29
Dermata Therapeutics Q3 2026 net loss widens 67% to USD 2.82 million
  • Dermata Therapeutics’ third-quarter 2026 net loss widened 67% year over year to USD 2.82 million.
  • Net sales reached USD 74,000 following the August 25 launch of Tome Foundational Treatment, its first commercial product.
  • Selling, general and administrative expenses more than doubled year over year to USD 2.76 million, primarily due to commercialization activities.
  • Cash, cash equivalents and restricted cash totaled USD 5.02 million at September 30, sufficient to fund operations into the first quarter of 2027.
  • Tome Clearing Treatment entered clinical evaluation in October, with a commercial launch expected in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.